A Phase 1 interventional study of Elecoglipron and Atorvastatin in Healthy Participants, sponsored by AstraZeneca. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.
Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 9 that started in 2026, is one of 11 in phase 1, and was the 12th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China, Hong Kong, Malaysia and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
AstraZeneca · Sites in United States, Bulgaria, China and 13 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 57 across the 18 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 197th largest by enrollment of the 280 interventional ones that give a count, is one of 14 that started in 2026, is one of 86 in phase 1, reaches primary completion later than 1 of the 14 other live ones, and was the 334th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing elecoglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07534592AstraZenecaA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | 2027-01-25 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.
This is an open-label, fixed-sequence, conducted at 2 study centers with 2 groups.
Group 1 is designed to assess the PK of atorvastatin in healthy participants when administered alone and in combination with multiple doses of elecoglipron. This group will consist of a screening period, 6 treatment periods, and a follow-up visit. Each participant in Group 1 will be involved in the study for approximately 15 weeks.
Group 2 is designed to assess the PK of rosuvastatin in healthy participants when administered alone and in combination with multiple doses of elecoglipron. This group will consist of a screening period, 7 treatment periods, and a follow-up visit. Each participant in Group 2 will be involved in the study for approximately 16 weeks.
Group 1 and Group 2 are independent and non-sequential parts in this study. All parts of this study will be performed in healthy male and female participants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of atorvastatin on Day 1.
Drug: Atorvastatin
Participants will receive single dose of atorvastatin on Day 5 and then receive multiple doses of elecoglipron from Day 7 to Day 40.
Drug: Elecoglipron · Drug: Atorvastatin
Participants will receive single dose of atorvastatin on Day 41 and then receive multiple doses of elecoglipron from Day 41 to Day 43.
Drug: Elecoglipron · Drug: Atorvastatin
Participants will receive elecoglipron in the morning and a single dose of atorvastatin in the evening on Day 44. Participant will continue elecoglipron on Day 45. Participants will receive daily administration of different doses of elecoglipron alone from Day 46 to Day 58.
Drug: Elecoglipron · Drug: Atorvastatin
Participants will receive single dose of atorvastatin and elecoglipron on Day 59. Participants will receive elecoglipron alone on Day 60 to Day 61.
Drug: Elecoglipron · Drug: Atorvastatin
Participants will receive elecoglipron in the morning and a single dose of atorvastatin in the evening on Day 62. Participant will continue elecoglipron alone from Day 63 to Day 64.
Drug: Elecoglipron · Drug: Atorvastatin
Participants will receive single dose of rosuvastatin on Day 1 and then multiple doses of elecoglipron from Day 5 to Day 38.
Drug: Elecoglipron · Drug: Rosuvastatin
Participants will receive elecoglipron in the morning along with a single dose of rosuvastatin on Day 39. Participant will continue elecoglipron alone from Day 40 to Day 44.
Drug: Elecoglipron · Drug: Rosuvastatin
Participants will receive elecoglipron in the morning and a single dose of rosuvastatin in the evening on Day 45. Participant will continue on different doses of elecoglipron alone from Day 46 to Day 59.
Drug: Elecoglipron · Drug: Rosuvastatin
Participants will receive elecoglipron in the morning along with a single dose of rosuvastatin on Day 60. Participant will continue elecoglipron alone from Day 61 to Day 65.
Drug: Elecoglipron · Drug: Rosuvastatin
Participants will receive elecoglipron in the morning and a single dose of rosuvastatin in the evening on Day 66. Participant will continue on elecoglipron alone from Day 67 to Day 69 and from Day 73 to Day 86.
Drug: Elecoglipron · Drug: Rosuvastatin
Participants will receive elecoglipron and a single dose of rosuvastatin in the morning on Day 87. Participants will continue elecoglipron from Day 87 to Day 91.
Drug: Elecoglipron · Drug: Rosuvastatin
Participants will receive a single dose of rosuvastatin in the morning on Day 106.
Drug: Rosuvastatin
Elecoglipron will be administered as oral tablet.
Atorvastatin will be administered as oral tablet.
Rosuvastatin will be administered as oral tablet.
Area under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
Maximum observed drug concentration (Cmax) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
AUCinf of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
AUClast of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
Cmax of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUCinf (R AUCinf) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUClast (R AUClast) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on Cmax (R Cmax) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
Terminal elimination half-life (t1/2λz) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
Terminal rate constant (λz) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
Time to reach maximum observed concentration (tmax) of atorvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of atorvastatin in healthy participants.
Time frame: Group 1: Day 1 to Day 71
Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUCinf (R AUCinf) of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUClast (R AUClast) of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on Cmax (R Cmax) of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
t1/2λz of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
λz of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
tmax of rosuvastatin
To assess the effect of multiple doses of elecoglipron on the PK of a single dose of rosuvastatin in healthy participants.
Time frame: Group 2: Day 1 to Day 76
Number of participants with adverse events (AEs) and adverse event of special interest (AESI)
To examine the safety and tolerability of elecoglipron alone and in combination with atorvastatin (Group 1) or rosuvastatin (Group 2) in healthy participants.
Time frame: Group 1: Day -28 to Day 74; Group 2: Day -28 to Day 79
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptriaIs.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/ Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 9 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Jan 2027 and completion Oct 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elecoglipron · Atorvastatin · Rosuvastatin